377 related articles for article (PubMed ID: 24519556)
1. Current role of FDG PET/CT in lymphoma.
Kostakoglu L; Cheson BD
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):1004-27. PubMed ID: 24519556
[TBL] [Abstract][Full Text] [Related]
2. FDG-PET/CT in lymphoma.
Juweid ME
Methods Mol Biol; 2011; 727():1-19. PubMed ID: 21331925
[TBL] [Abstract][Full Text] [Related]
3. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Qiu L; Chen Y; Wu J
Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
[TBL] [Abstract][Full Text] [Related]
4. PET/CT: appropriate application in lymphoma.
Wang X
Chin Clin Oncol; 2015 Mar; 4(1):4. PubMed ID: 25841711
[TBL] [Abstract][Full Text] [Related]
5. FDG PET/CT imaging as a biomarker in lymphoma.
Meignan M; Itti E; Gallamini A; Younes A
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(4):623-33. PubMed ID: 25573631
[TBL] [Abstract][Full Text] [Related]
6. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
7. The role of FDG-PET imaging in the management of lymphoma.
Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
[TBL] [Abstract][Full Text] [Related]
8. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
[TBL] [Abstract][Full Text] [Related]
9. [Importance of PET/CT in lymphoma diagnostics].
Afshar-Oromieh A; Kratochwil C; Haberkorn U; Giesel FL
Radiologe; 2012 Apr; 52(4):338-46. PubMed ID: 22526115
[TBL] [Abstract][Full Text] [Related]
10. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma.
Blum RH; Seymour JF; Wirth A; MacManus M; Hicks RJ
Clin Lymphoma; 2003 Jun; 4(1):43-9. PubMed ID: 12837154
[TBL] [Abstract][Full Text] [Related]
11. Role of PET in lymphoma.
Schwaiger M; Wieder H
Chang Gung Med J; 2005 May; 28(5):315-25. PubMed ID: 16086546
[TBL] [Abstract][Full Text] [Related]
12. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.
Ngeow JYY; Quek RHH; Ng DCE; Hee SW; Tao M; Lim LC; Tan YH; Lim ST
Ann Oncol; 2009 Sep; 20(9):1543-1547. PubMed ID: 19474116
[TBL] [Abstract][Full Text] [Related]
13. PET/computed tomography and lymphoma.
Allen-Auerbach M; de Vos S; Czernin J
Radiol Clin North Am; 2013 Sep; 51(5):833-44. PubMed ID: 24010908
[TBL] [Abstract][Full Text] [Related]
14. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas.
Kumar R; Maillard I; Schuster SJ; Alavi A
Radiol Clin North Am; 2004 Nov; 42(6):1083-100. PubMed ID: 15488559
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 18F-FDG Pet/CT and CT: diagnosis performance in lymphoma patient after treatment.
Chiewvit S; Thephamongkhol K; Ubolnuch K; Pooliam J; Phongsawat N; Chiewvit P
J Med Assoc Thai; 2014 Jan; 97(1):85-94. PubMed ID: 24701734
[TBL] [Abstract][Full Text] [Related]
16. Value of FDG-PET/CT examinations in different cancers of children, focusing on lymphomas.
Bárdi E; Csóka M; Garai I; Szegedi I; Müller J; Györke T; Kajáry K; Nemes K; Kiss C; Kovács G
Pathol Oncol Res; 2014 Jan; 20(1):139-43. PubMed ID: 23955198
[TBL] [Abstract][Full Text] [Related]
17. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management.
Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560
[TBL] [Abstract][Full Text] [Related]
18. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography.
Stumpe KD; Urbinelli M; Steinert HC; Glanzmann C; Buck A; von Schulthess GK
Eur J Nucl Med; 1998 Jul; 25(7):721-8. PubMed ID: 9662594
[TBL] [Abstract][Full Text] [Related]
19. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Specht L
Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
[TBL] [Abstract][Full Text] [Related]
20. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients.
Allen-Auerbach M; de Vos S; Czernin J
Radiol Clin North Am; 2008 Mar; 46(2):199-211, vii. PubMed ID: 18619376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
